Table 11.

—[Section 3.2] Summary of Findings: Should LMWH vs Placebo Be Used for DVT Prevention in Critically Ill Adult Patients?^12,70

Outcome	No. of Participants (Studies) Follow-up	Quality of the Evidence (GRADE)	Relative Effect (95% CI)	Anticipated Absolute Effects
				Baseline Risk	Risk difference with LMWH (95% CI)
Symptomatic DVT	1,437 (1 RCT) 5-28 d	Moderate due to serious imprecisiona	RR, 0.82 (0.51-1.32)	58 per 1,000	6 fewer (from 23 fewer to 22 more)
Pulmonary embolus	1,437 (1 RCT) 5-28 d	Very low due to very serious imprecisionb and indirectnessc	RR, 1.01 (0.31-3.31)	42 per 1,000	1 more (from 29 fewer to 97 more)
Death	169 (1 RCT) 5-28 d	Low due to very serious imprecisiona	RR, 1.01 (0.40-2.57)	94 per 1,000	1 more per 1,000 (from 56 fewer to 148 more)
Major bleeding	221 (1 RCT) 5-28 d	Low due to very serious imprecisiona	RR, 2.09 (0.54 -8.16)	27 per 1,000	29 more per 1,000 (from 12 fewer to 190 more)

See Table 1 and 4 legends for expansion of abbreviations.

^aCIs include appreciable harms and benefits.

^bThe RR of the outcome of PE is considered very imprecise due to small number of events (4 of 478 LMWH vs 8 of 959 placebo).

^cRR estimated from a mix of symptomatic and asymptomatic events.